Cooperative group research efforts in lung cancer 2008: Focus on advanced-stage non-small-cell lung cancer

Heather Wakelee, Kemp Kernstine, Everett Vokes, Joan Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Laurie Gaspar, David R. Gandara, Hak Choy, Joe Bill Putnam

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Clinical trials performed within the cooperative group system play a substantial role in the advancing of lung cancer therapy. Interactions between the leaders of the cooperative groups are critical and occur regularly throughout the year, but the annual Lung Cancer Congress provides a unique forum for representatives from each group to present ongoing and planned studies in an interactive forum. Herein, we highlight discussion from the 9th annual Lung Cancer Congress in June 2008, focused on advanced-stage non-small-cell lung cancer (NSCLC). Many studies are looking at the addition of targeted agents such as bevacizumab, cetuximab, vascular endothelial growth factor receptor inhibitors, and apoptosis-inducing agents to chemotherapy. Personalizing therapy by better selection of patients for particular drugs is also being emphasized, most notably epidermal growth factor receptor fluorescence in situ hybridization overexpression and other predictions of response with cetuximab. Future articles in this series will address early and locally advanced NSCLC as well as other thoracic malignancies such as small-cell lung cancer and mesothelioma. Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)346-351
Number of pages6
JournalClinical Lung Cancer
Volume9
Issue number6
DOIs
StatePublished - Nov 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Research
Vascular Endothelial Growth Factor Receptor
Mesothelioma
Small Cell Lung Carcinoma
Fluorescence In Situ Hybridization
Epidermal Growth Factor Receptor
Patient Selection
Thorax
Therapeutics
Clinical Trials
Apoptosis
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Cetuximab

Keywords

  • Chemotherapy
  • Clinical trials
  • Epidermal growth factor receptor
  • Fluorescence in situ hybridization

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Cooperative group research efforts in lung cancer 2008 : Focus on advanced-stage non-small-cell lung cancer. / Wakelee, Heather; Kernstine, Kemp; Vokes, Everett; Schiller, Joan; Baas, Paul; Saijo, Nagahiro; Adjei, Alex; Goss, Glenwood; Gaspar, Laurie; Gandara, David R.; Choy, Hak; Putnam, Joe Bill.

In: Clinical Lung Cancer, Vol. 9, No. 6, 11.2008, p. 346-351.

Research output: Contribution to journalArticle

Wakelee, H, Kernstine, K, Vokes, E, Schiller, J, Baas, P, Saijo, N, Adjei, A, Goss, G, Gaspar, L, Gandara, DR, Choy, H & Putnam, JB 2008, 'Cooperative group research efforts in lung cancer 2008: Focus on advanced-stage non-small-cell lung cancer', Clinical Lung Cancer, vol. 9, no. 6, pp. 346-351. https://doi.org/10.3816/CLC.2008.n.050
Wakelee, Heather ; Kernstine, Kemp ; Vokes, Everett ; Schiller, Joan ; Baas, Paul ; Saijo, Nagahiro ; Adjei, Alex ; Goss, Glenwood ; Gaspar, Laurie ; Gandara, David R. ; Choy, Hak ; Putnam, Joe Bill. / Cooperative group research efforts in lung cancer 2008 : Focus on advanced-stage non-small-cell lung cancer. In: Clinical Lung Cancer. 2008 ; Vol. 9, No. 6. pp. 346-351.
@article{05f98231473f4af08520b3c43e14b124,
title = "Cooperative group research efforts in lung cancer 2008: Focus on advanced-stage non-small-cell lung cancer",
abstract = "Clinical trials performed within the cooperative group system play a substantial role in the advancing of lung cancer therapy. Interactions between the leaders of the cooperative groups are critical and occur regularly throughout the year, but the annual Lung Cancer Congress provides a unique forum for representatives from each group to present ongoing and planned studies in an interactive forum. Herein, we highlight discussion from the 9th annual Lung Cancer Congress in June 2008, focused on advanced-stage non-small-cell lung cancer (NSCLC). Many studies are looking at the addition of targeted agents such as bevacizumab, cetuximab, vascular endothelial growth factor receptor inhibitors, and apoptosis-inducing agents to chemotherapy. Personalizing therapy by better selection of patients for particular drugs is also being emphasized, most notably epidermal growth factor receptor fluorescence in situ hybridization overexpression and other predictions of response with cetuximab. Future articles in this series will address early and locally advanced NSCLC as well as other thoracic malignancies such as small-cell lung cancer and mesothelioma. Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer.",
keywords = "Chemotherapy, Clinical trials, Epidermal growth factor receptor, Fluorescence in situ hybridization",
author = "Heather Wakelee and Kemp Kernstine and Everett Vokes and Joan Schiller and Paul Baas and Nagahiro Saijo and Alex Adjei and Glenwood Goss and Laurie Gaspar and Gandara, {David R.} and Hak Choy and Putnam, {Joe Bill}",
year = "2008",
month = "11",
doi = "10.3816/CLC.2008.n.050",
language = "English (US)",
volume = "9",
pages = "346--351",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Cooperative group research efforts in lung cancer 2008

T2 - Focus on advanced-stage non-small-cell lung cancer

AU - Wakelee, Heather

AU - Kernstine, Kemp

AU - Vokes, Everett

AU - Schiller, Joan

AU - Baas, Paul

AU - Saijo, Nagahiro

AU - Adjei, Alex

AU - Goss, Glenwood

AU - Gaspar, Laurie

AU - Gandara, David R.

AU - Choy, Hak

AU - Putnam, Joe Bill

PY - 2008/11

Y1 - 2008/11

N2 - Clinical trials performed within the cooperative group system play a substantial role in the advancing of lung cancer therapy. Interactions between the leaders of the cooperative groups are critical and occur regularly throughout the year, but the annual Lung Cancer Congress provides a unique forum for representatives from each group to present ongoing and planned studies in an interactive forum. Herein, we highlight discussion from the 9th annual Lung Cancer Congress in June 2008, focused on advanced-stage non-small-cell lung cancer (NSCLC). Many studies are looking at the addition of targeted agents such as bevacizumab, cetuximab, vascular endothelial growth factor receptor inhibitors, and apoptosis-inducing agents to chemotherapy. Personalizing therapy by better selection of patients for particular drugs is also being emphasized, most notably epidermal growth factor receptor fluorescence in situ hybridization overexpression and other predictions of response with cetuximab. Future articles in this series will address early and locally advanced NSCLC as well as other thoracic malignancies such as small-cell lung cancer and mesothelioma. Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer.

AB - Clinical trials performed within the cooperative group system play a substantial role in the advancing of lung cancer therapy. Interactions between the leaders of the cooperative groups are critical and occur regularly throughout the year, but the annual Lung Cancer Congress provides a unique forum for representatives from each group to present ongoing and planned studies in an interactive forum. Herein, we highlight discussion from the 9th annual Lung Cancer Congress in June 2008, focused on advanced-stage non-small-cell lung cancer (NSCLC). Many studies are looking at the addition of targeted agents such as bevacizumab, cetuximab, vascular endothelial growth factor receptor inhibitors, and apoptosis-inducing agents to chemotherapy. Personalizing therapy by better selection of patients for particular drugs is also being emphasized, most notably epidermal growth factor receptor fluorescence in situ hybridization overexpression and other predictions of response with cetuximab. Future articles in this series will address early and locally advanced NSCLC as well as other thoracic malignancies such as small-cell lung cancer and mesothelioma. Ongoing trials within the cooperative groups are an essential component of the persistent improvement in the treatment of lung cancer.

KW - Chemotherapy

KW - Clinical trials

KW - Epidermal growth factor receptor

KW - Fluorescence in situ hybridization

UR - http://www.scopus.com/inward/record.url?scp=59449106057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449106057&partnerID=8YFLogxK

U2 - 10.3816/CLC.2008.n.050

DO - 10.3816/CLC.2008.n.050

M3 - Article

C2 - 19073517

AN - SCOPUS:59449106057

VL - 9

SP - 346

EP - 351

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -